The first HFMD vaccine in China will enter the field for inspection and is expected to be approved within this year

According to the information on the website of CFDA on May 11, the inactivated enterovirus 71 vaccine (human diploid cells) from the Institute of medical biology, Chinese Academy of medical sciences will enter the drug registration production and GMP field inspection at the same time this month According to the drug review process, the product is expected to be approved for production within half a year, which will become the first HFMD vaccine in China Public information shows that hand foot mouth disease is a kind of children's infectious disease, which mostly occurs in children under 5 years old It can cause herpes in hands, feet, mouth and other parts A few children can cause complications such as myocarditis, pulmonary edema, aseptic meningeal encephalitis, etc if the disease develops rapidly in some severe children, it will lead to death HFMD is often caused by enterovirus EV71 infection, and there is no corresponding vaccine at home and abroad HFMD vaccine is one of the varieties with urgent domestic demand and great market potential, and there are not a few enterprises involved in research and development In addition to the Institute of medical biology, Chinese Academy of Medical Sciences, science and Technology (NASDAQ: SVA) and Wuhan Institute of Biological Products Co., Ltd have also applied for the production approval documents of the vaccine At present, they are both in the review stage and the R & D progress is ahead In addition, Beijing green bamboo Biological Pharmaceutical Co., Ltd., a subsidiary of Hualan Biology (002007 SZ) and Zhifei Biology (300122 SZ), has applied for the clinical approval of HFMD vaccine.